August 2026 - Increased Prostaglandin Activity pharmaceutical patent expiration information, FTO search

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Thea Pharma	ZIOPTAN	tafluprost	SOLUTION/DROPS;OPHTHALMIC	202514-001	Feb 10, 2012	AT	RX	Yes	Yes	10,864,159	⤷ Start Trial	Y			⤷ Start Trial
Thea Pharma	ZIOPTAN	tafluprost	SOLUTION/DROPS;OPHTHALMIC	202514-001	Feb 10, 2012	AT	RX	Yes	Yes	9,999,593	⤷ Start Trial	Y			⤷ Start Trial
Sandoz	TAFLUPROST	tafluprost	SOLUTION/DROPS;OPHTHALMIC	209040-001	Jan 28, 2022	AT	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 4, 2026

Market dynamics and patent landscape for drugs that increase prostaglandin activity

Increased prostaglandin activity spans multiple drug classes: prostaglandin analogs and prostaglandin receptor agonists (eg, latanoprost, travoprost, bimatoprost), prostaglandin pathway enzyme modulators (eg, COX-1/COX-2 inhibitors), thromboxane/prostacyclin axis drugs (eg, selexipag, beraprost), and “prostaglandin-like” receptor agonists (eg, misoprostol). Across these areas, exclusivity is driven by (1) composition and formulation patents, (2) device-delivery and dosing regimens, and (3) method-of-use (patient population, disease stage, combination regimens). Competitive pressure shifts toward follow-on receptor agonists and combination products as patent estates narrow, with frequent litigation or at-risk launches in glaucoma, pulmonary arterial hypertension (PAH), and GI protection.

This article maps the patent and market mechanics by major indications where prostaglandin activity is pharmacologically central. It also outlines how to model generic or biosimilar-style entry risk for small molecules and how Orange Book listings typically evolve around follow-on reformulations.

Which drugs increase prostaglandin activity and what market segments do they dominate?

Drugs that increase prostaglandin activity (directly or via receptor agonism or pathway enhancement) cluster into several high-revenue therapeutic segments.

Glaucoma and ocular hypertension

Prostaglandin receptor agonists are first-line options in many markets and remain among the highest-persistence categories due to once-daily dosing and strong intraocular pressure (IOP) efficacy.

Common actives include:

Latanoprost (prostanoid receptor agonist; latanoprost acid metabolite)
Travoprost
Bimatoprost (mechanistically distinct in that it is not strictly a classic FP agonist; it increases prostaglandin-related signaling and aqueous humor outflow pathways)
Tafluprost

Key market dynamic: brand differentiation has shifted from “first in class” molecules to delivery and dosing optimizations, including higher-concentration solutions, preservative strategies, and fixed-dose combinations.

Pulmonary arterial hypertension (PAH)

The PAH prostacyclin pathway is central:

Selexipag (prostacyclin receptor agonist; IP receptor signaling increases downstream prostacyclin effects)
Treprostinil (prostacyclin analog; multiple dosage forms)
Epoprostenol (prostacyclin analog; limited formulation shelf-life drives product-specific IP)

Key market dynamic: clinical and payer focus on tolerability and route-of-administration convenience increases leverage for newer delivery systems and combination strategies.

GI protection and NSAID-associated ulcers

Prostaglandin analog:

Misoprostol

Market dynamic: after initial exclusivity cycles, risk for rapid generic erosion is structurally high because generic chemistry is straightforward and regulation does not create product-specific exclusivity beyond listing-specific patents.

Thromboxane/prostacyclin balance and vascular indications

Beraprost (prostacyclin analog)
Iloprost (prostacyclin analog; region-specific availability)

Market dynamic: smaller addressable populations mean fewer overlapping blockbuster patents, but local filings and manufacturing method patents still matter for entry timing.

Inflammation and pain (prostanoid pathway inhibitors)

Although COX inhibitors reduce prostaglandins rather than increase them, they compete for the same prescribing space and are central to prostanoid pathway IP landscapes. Their patent timelines also affect payer and formulary decisions for prostaglandin-adjacent products.

What patents protect drugs that increase prostaglandin activity?

Patent estates usually combine core chemical IP with a “second layer” of product and use IP. For prostaglandin-activity drugs, the most litigated and commercially leveraged buckets are:

Composition of matter and prodrug/metabolite claims

Core molecule claims (active ingredient)
Salt forms and stereochemistry
Prodrug esterification strategies (notably for ocular latanoprost/travoprost approaches where the metabolite is the active species)

Formulation patents

Common claim types:

Concentration ranges (eg, 0.005% latanoprost solution)
Buffer and pH windows that stabilize prostanoid analogs
Surfactants and solubilizers
Preservative systems (and preservative-free variants)
Osmolality and tonicity for ocular drops
Stability to oxidation or hydrolysis for prostacyclin analogs

Device and delivery system patents (especially ocular and parenteral)

Ophthalmic drop applicator design
Metered-dose or pump delivery systems
Implant or sustained-release formulations (where applicable)
Infusion set modifications and stabilization approaches for prostacyclin infusion products

Method-of-use patents

Frequent claim patterns:

Specific dosing regimens (timing, frequency, duration)
Patient subpopulations (baseline IOP ranges, disease severity)
Combination with other glaucoma agents (beta-blockers, alpha agonists, carbonic anhydrase inhibitors)
PAH background therapy combinations (with endothelin receptor antagonists or other prostacyclin pathway agents)

Manufacturing method patents

Particularly relevant for:

Prostacyclin analogs with stability constraints
Sterile fill-finish processes
Lyophilization and reconstitution methods
Purification parameters affecting impurity profiles

Orange Book listing mechanics

For FDA small-molecule approvals, the key practical proxy is the Orange Book “listed patents” set:

Drug substance and drug product patents
Methods of use tied to a specific FDA-approved indication
Sometimes combination patents tied to fixed-dose products

The litigation and launch calculus depends on how many patents remain “Orange Book listed” and whether ANDA filers can design around the claims.

How strong is the patent estate for prostaglandin-activity drugs in key indications?

Patent strength is best evaluated as a function of:

number of Orange Book listed patents remaining at the time of generic entry (for small molecules),
breadth of claim coverage across formulation and use,
history of Paragraph IV challenges and settlements, and
whether multiple products compete within the same class with interlocking patents.

Glaucoma: follow-on penetration with layered formulation IP

Glaucoma prostaglandin analogs show:

multiple generations of formulation and delivery changes
method-of-use and combination patents that can extend exclusionary effects even when core compound coverage has weakened

This structure tends to delay full generic takeout and supports a long runway for “brand-like” follow-on products (including combination drops).

PAH: route and formulation drive durable differentiation

PAH prostacyclin pathway drugs face:

device and infusion logistics IP
stability and sterile manufacturing constraints that support formulation-specific exclusivity
persistent method-of-use claims tied to patient risk stratification and background therapy

Even where chemical entities become generic, product-specific patents and enforceable formulation claims can slow substitution in practice.

GI: generally weaker follow-on and faster generic erosion

Misoprostol’s market often reflects:

earlier expiration of composition patents
limited room for formulation moat building that survives generic design-around

As a result, generic entry tends to be earlier and more definitive.

When do drugs that increase prostaglandin activity lose exclusivity, and what are the typical transition points?

For prostaglandin-activity drugs, exclusivity transitions typically occur in stages:

Stage 1: composition-of-matter expiry

When active ingredient protection ends, ANDA filers still face:

formulation and method-of-use listed patents
exclusivity tied to specific FDA approvals or new dosage forms

Stage 2: formulation and method-of-use patent cliffs

Even after the core expires, litigation often targets:

concentration and buffer/pH windows
preservative systems
dosing regimens and combination indication claims

Stage 3: device/manufacturing design-around

For ocular and parenteral products, generic feasibility depends on:

whether the method patents remain enforceable
whether the generics can achieve comparable stability and performance without using claimed methods

Stage 4: practical substitution and payer adoption

Even with patent expiry, switching can be slow due to:

prescriber confidence
patient stability on existing drops or infusion regimens
pharmacy and payer contracting

What patent litigation affects prostaglandin-activity drugs the most?

Litigation is concentrated in categories where:

multiple patents are listed for each reference product, and
ANDA filers can plausibly challenge at least some claims.

Typical litigation pressure points:

Paragraph IV challenges against method-of-use and formulation patents
settlement agreements that provide “design-around” pathways or delayed launch windows
disputes over Orange Book patent listing adequacy

In glaucoma, litigation often aligns with:

combination products and preservative-free reformulations
dosing frequency and patient population claims

In PAH, disputes commonly align with:

formulation stability and route-of-administration-specific claims
manufacturing process and sterile fill/finish

What Paragraph IV challenges and settlements signal generic entry risk?

Paragraph IV activity is the best leading indicator for:

timing of near-term generic launch
which patents are most vulnerable (frequent targets are formulation and method-of-use)

Settlement patterns in prostaglandin-activity drugs typically follow two practical outcomes:

delayed launch in exchange for consideration or licensing terms, with agreed “non-infringement” workarounds
design-around that permits launch at an earlier date but avoids claim coverage through formulation or method changes

What is the Orange Book status of prostaglandin-activity drugs?

Orange Book status determines whether an ANDA applicant must certify to each listed patent and whether litigation must be filed.

A practical Orange Book-driven forecast:

High count of listed patents across drug substance, drug product, and method-of-use increases friction.
When many listed patents expire around the same time, multiple “certification strategies” occur.
If only a small subset remains, generic entry tends to focus on design-around for those specific patents.

For business planning, the key metric is the number of remaining Orange Book listed patents that are both:

plausibly infringed by generic design, and
not previously weakened via settlements or adverse rulings.

What formulations are protected by patents for increased prostaglandin activity?

Formulation patenting is especially active where:

the molecule is chemically unstable
preservatives raise tolerability concerns
device delivery impacts pharmacokinetics

Ophthalmic prostaglandin analogs

Common formulation IP targets:

concentration and pH
viscosity and solubilizer systems
preservative type and concentration
preservative-free delivery approaches (single-use units)
particulate and filter system compatibility

Prostacyclin and prostacyclin receptor agonists (PAH)

Common formulation IP targets:

stability in solution vs lyophilized state
reconstitution and infusion compatibility
impurity profile control
sterile manufacturing method parameters

How does increased prostaglandin activity compare across competing drug classes and products?

Glaucoma: prostaglandin analogs vs alternatives

Prostaglandin receptor agonists compete primarily against:

beta-blockers
alpha agonists
carbonic anhydrase inhibitors
rho-kinase inhibitors (where present)

Within the prostaglandin class, “competition” is defined by:

IOP reduction magnitude and durability
side effect profiles (notably ocular hyperemia and periorbital effects)
preservative and dosing convenience

Patent estates shape how quickly formulary substitution occurs once a “newer” follow-on launches.

PAH: prostacyclin pathway products vs endothelin and sGC agents

Prostacyclin pathway drugs compete within a multi-mechanism PAH treatment landscape:

endothelin receptor antagonists (ERAs)
soluble guanylate cyclase (sGC) stimulators
combination regimens that incorporate prostacyclin effects

Patent estates influence:

ability to lock in combination regimens through method-of-use patents
ability to defend route-of-administration advantages (oral vs infusion)

What generic entry risks exist for prostaglandin-activity drugs?

Generic risk depends on whether the “last mile” patents are still enforceable:

Formulation and method-of-use patents are the primary barrier after composition expiry.
Device and manufacturing method patents can create operational barriers if claim scope is broad.

Entry is also slowed when:

the reference product is a complex route (infusion-based)
stability and sterile manufacturing make generic equivalence harder

Which companies are challenging patents for prostaglandin-activity drugs?

Patent challenges are commonly filed by:

major ANDA generic manufacturers targeting large markets
regional entrants with niche ocular or PAH product development capabilities

For a business-grade view, the critical question is not the identity of the generic filer but:

which listed patents they target,
whether they file with viable certification strategies (Paragraph IV vs section viii carve-outs for methods),
and whether settlements cap at-risk entry dates.

A true company-by-company list requires product-specific Orange Book and docket review.

Key timeline mechanics for prostaglandin-activity drugs: what to model for entry planning?

For pipeline and licensing strategy, model these time axes:

Core patent expiry date
- Defines chemical entry feasibility.
Secondary patent “tail” (formulation + method-of-use)
- Defines real launch feasibility under Orange Book constraints.
Exclusivity windows
- 180-day ANDA exclusivity for first filer (when triggered).
Litigation and settlement dates
- Define practical at-risk launch timing.
Regulatory pathway timing
- ANDA approval timelines after dispute resolution.
Commercial substitution
- Payer and prescriber adoption, often slower than patent expiry.

Key Takeaways

Prostaglandin-activity drugs are dominated by long-lived IP that shifts from composition to formulation, method-of-use, and delivery-system patents.
Glaucoma and PAH show the most persistent patent friction because of layered formulation and dosing regimen claims that support combination and follow-on product defenses.
GI prostaglandin analogs tend to experience faster generic erosion after core patent expiry, reflecting lower formulation and delivery complexity.
Orange Book patent count and the remaining set of formulation and method-of-use patents are the leading indicators of generic entry risk.
Litigation and settlements usually cluster around the “tail” patents, making claim vulnerability a direct driver of launch timing.

FAQs

1) What drives follow-on patenting for latanoprost and other prostaglandin analog eye drops?
Formulation stability, preservative and pH optimization, preservative-free delivery approaches, and method-of-use/combinational indication claims.

2) Do patents on dosing regimens matter for prostaglandin-activity therapies?
Yes. Method-of-use claims tied to dosing schedule, patient subsets, and background therapy can delay generic entry even after composition expiry.

3) What is the biggest barrier to generic substitution for prostacyclin pathway PAH drugs?
Route-specific formulation and sterile manufacturing method patents, plus enforceable method-of-use claims tied to dosing and combination regimens.

4) How does Orange Book patent listing affect ANDA launch timing?
Each listed patent forces certification and can trigger litigation. The remaining tail of listed formulation and method-of-use patents most often determines the feasible launch date.

5) What settlement structures most commonly control at-risk entry?
Agreements that provide delayed launch dates, design-around formulation changes, and sometimes licensing arrangements that narrow infringement risk.

References (APA)

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (FDA database).
U.S. Food and Drug Administration. Drugs@FDA. (FDA database).